Endpoints News

Exclusive: A new genetic medicine startup is picking up where Editas and Biogen left off. endpoints.news/genetic-medici…

Erasca prices a $550M offering; Summit offloads an antibiotic. endpoints.news/erascas-550m-o…

An unexpected dose response clouds the outlook for Biogen's Alzheimer's tau drug. endpoints.news/biogens-tau-dr…

Fresh off a $4.7B Novo deal, the Akero team resurfaces with a new I&I company and a China drug. endpoints.news/former-akero-t…

FDA rejects Tris Pharma's narcolepsy drug; Agenus abandons its Phase 3 colorectal cancer program. endpoints.news/tris-pharmas-c…

Biopharma enters earnings season on the back of a breakout M&A year. endpoints.news/busy-ma-activi…

Apnimed files for an IPO with an FDA decision on its sleep apnea drug on the horizon. endpoints.news/apnimed-files-…

Germany passes drug pricing reform — and pharma is threatening to leave. endpoints.news/german-lawmake…

American drugmakers are going dark as China's biotech competition intensifies. endpoints.news/us-biotechs-tu…

An AI biotech saw something in Novo's Parkinson's stem cell therapy. Here's what the data showed. endpoints.news/the-data-that-…

Pfizer names an obesity discovery head; Xaira reshuffles its leadership. endpoints.news/pfizer-appoint…

ARPA-H is awarding up to $160M across seven teams to develop custom gene editing treatments for rare diseases, though some researchers involved say the funding falls short of initial expectations. endpoints.news/arpa-h-bookmar…

FDA has quietly paused its public release of complete response letters, after a law firm's citizen petition raised litigation concerns over the sensitive information they contain. endpoints.news/fda-quietly-st…

Lilly has made 11 biotech acquisitions so far in 2026, more than its prior three years combined. endpoints.news/eli-lilly-domi…

Two more days to nominate someone for our @endpts Women in Biopharma series, led by @Nicole_DeFeudis. The form closes end of day July 10. endpoints.news/endpoints-wome…

GSK is ending its neurodegenerative disease pact with Alector after both partnered candidates failed in late-stage trials. endpoints.news/gsk-walks-away…

Stay tuned for topics, speakers and tickets. If you've got somebody great we should consider, DM me. They need to have first-hand expertise, be willing to state and defend their positions, and be a gripping speaker. And if you'd like to join in the audience, DM as well.

We've got several great participants lined up already. Our goal was to get out of the surface-level conversations about the US-China biotech, and give smart insiders a place to talk through focused issue in-depth.

🎙️🇨🇳The China Biotech Debate: Aug. 6 in Boston🇺🇸📣 Excited to share that we'll be hosting our first (of at least two) debate and discuss events about the rise of China biotech, what it means for the patients, companies + investors across the🌎! More details in coming days...

AstraZeneca shares fell after its heart drug Wainua, developed with Ionis, failed to beat placebo in a Phase 3 trial for the cardiac condition ATTR-CM. endpoints.news/astrazeneca-si…